Clinical trial · Observational
Long Term Implications of Rare Brain Tumours'
Understanding the Long-term Implications of Treatment of Rare Brain Tumours on Health-related Quality of Life: A European Cross-sectional Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients diagnosed with oligodendroglioma with a specific molecular profile represent rare tumour groups (about 10% of adult gliomas) with relatively favourable prognosis (median survival between 8 and 12 years). These patients are often treated with surgery, chemotherapy and/or radiotherapy. However, as patients live for a long period of time, they may also experience long-term toxic side-effects of treatment. The long-term consequences of treatment- and disease-related factors on quality of life and cognitive functioning of these patients are largely unknown. This study aims to investigate quality of life and cognitive functioning in long-term survivors of oligodendroglioma (with IDH mutation and 1p/19q codeletion). This knowledge can support health care professionals prepare patients for any long-term consequences of treatment.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cognitive Impairment | — | UNRESOLVED | — |
| Health-related Quality of Life | — | UNRESOLVED | — |
| Long-term Effects of Cancer Treatment | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| WHO Grade III Oligodendroglial Tumor | Anaplastic Oligodendroglioma | ALIAS | 0.90 |
| WHO Grade II Oligodendroglial Tumor | Oligodendroglioma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cognitive Functioning | Other | — | UNRESOLVED |
| Fatigue | Other | — | UNRESOLVED |
| Health-related Quality of Life | Other | — | UNRESOLVED |
| Psychological Distress | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Oligodendroglioma (Grade II and III) Patients
- description
- Patients diagnosed with a WHO Grade II or III Oligodendroglioma
- interventionNames
- Other: Health-related Quality of Life
- Other: Psychological Distress
- Other: Fatigue
- Other: Cognitive Functioning
Primary outcomes (2)
- measure
- Health Related Quality of Life - EORTC QLQ-C30
- timeFrame
- through study completion, an average of 1 year
- description
- To assess the effects of an Oligodendroglioma diagnosis on health related quality of life, The EORTC QLQ-C30 assesses functioning domains (e.g. physical, emotional, role) and common cancer symptoms (e.g. fatigue, pain, nausea/vomiting, appetite loss - the higher the score of each item, the greater the intensity/frequency of the experience e.g., 'Have you had pain?' (1 = not at all, 2 = a little , 3 = quite a bit, 4 = very much)
- measure
- Disease Specific Quality of Life - EORTC QLQ-BN20
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed oligodendroglioma WHO grade II or III with IDH mutation and 1p/19q co-deletion * Diagnosis must have been ≥5 years ago * Patient is ≥18 years of age * Willing and able to provide written informed consent Exclusion Criteria: * They are expected to be unable to complete consent procedures and/or study outcomes due to legal incompetence or insufficient mastery of the language of the country in which they live as determined by their treating physician. * They do not provide written informed consent
References
Publications (1)
- DERIVEDBoele FW, Frances SM, Darlix A, Ducray F, Cartalat S, Guerdoux E, Tabouret E, Burger MC, Ryden I, Malmstrom A, Vauleon E, Kazda T, Renovanz M, Werner JM, Welsh L, Sanghera P, Dehais C, Desideri I, McBain C, Mehta S, Lord H, Jena R, Foweraker K, Ashkan K, Engelhardt J, Bourg V, Herrlinger U, Lawson McLean A, Hertler C, Haldbo-Classen L, Dahlrot RH, Noel G, Durando X, Hrab I, Razis E, Weller M, Muhic A, Klein M. Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation. Neuro Oncol. 2025 Nov 1;27(11):2959-2974. doi: 10.1093/neuonc/noaf172. PMID 40692477